Latest Capital Raising News

TrivarX Limited has announced the acquisition of Stabl-Im, a novel stable isotope MRI technology for early brain tumor detection, backed by a $4.2 million capital raise including investment from biotech leader Dr Daniel Tillett.

Ionic Rare Earths has expanded its capital raising to $15.6 million, driven by a $3 million strategic investment from US firm Argentem Creek Partners and strong shareholder support. The funds will accelerate projects across magnet recycling, rare earth refining, and US supply chain development.

Bannerman Energy Ltd reported a robust cash position of AUD 111.76 million at the end of September 2025, underpinning an estimated 13.5 quarters of operational funding despite ongoing exploration expenditures.

Native Mineral Resources reports a successful ramp-up of gold production at its Blackjack plant, delivering nearly 700 ounces of refined gold and securing $10 million in fresh capital to fuel ongoing operations and exploration.

Equity Story Group Ltd (ASX – EQS) has announced a fully underwritten renounceable entitlement offer to raise approximately $3.54 million, aiming to accelerate its entry into the property sector and strengthen working capital.

Eclipse Metals has commenced diamond drilling at its Greenland rare earth project, backed by a $4 million placement to expand and upgrade its resource. The move aligns with strategic plans for a Nasdaq dual listing amid growing global supply chain concerns.

EMVision Medical Devices’ latest Share Purchase Plan has attracted applications exceeding its initial $1 million target, with limited oversubscription capacity remaining ahead of the October 23 closing date.

Blue Star Helium Limited is advancing its Galactica helium project in Colorado, aiming for initial commercial production by December 2025, supported by a recent A$4.5 million equity raise.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

ActivEX Limited has completed a significant $800,000 share placement to True Creation Limited, aiming to strengthen its financial footing and advance exploration projects.

Biotron Limited is set to acquire Sedarex Limited, gaining global patents for SedRx, a next-generation general anaesthetic, supported by a $2.5 million capital raising to fund regulatory and development milestones.

Bod Science Limited reported a $576,000 net operating cash outflow for the September quarter, sustained by funding from Biortica Agrimed Limited under a Deed of Company Arrangement as it pursues a backdoor listing.